Shenyang Xingqi Pharmaceutical (300573.SZ): SQ-24071 eye drops phase I clinical trial first subject enrolled in the study.

Shenyang Xingqi Pharmaceutical (300573.SZ) announced that its research and development of SQ-24071 eye drops has completed the enrollment of the first subject in the "Phase I clinical trial of safety, tolerability, and pharmacokinetics of SQ-24071 eye drops in healthy participants receiving single/multiple doses in a single-center, randomized, double-blind, placebo-controlled study." The formal entry into the clinical trial has been initiated. The completion of enrollment of the first subject for SQ-24071 eye drops and the formal entry into the Phase I clinical trial will not have a significant impact on the company's recent performance.